/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Episode 216 - Tom Ciulla - CEO Ikarovec
Episode 216 - Tom Ciulla - CEO Ikarovec

Episode 216 - Tom Ciulla - CEO Ikarovec

The BioHub - by Avetix · Aug 17, 2026

Ikarovec CEO Tom Ciulla discusses their novel dual-function gene therapy targeting geographic atrophy by combining neuroprotection with complement modulation.

Practicing Clinician CEOs Gain an Edge by Witnessing Unmet Patient Needs Firsthand

Ikarovec's CEO, a part-time ophthalmologist, sees patients reject current treatments for geographic atrophy due to high treatment burden and limited benefit. This direct experience validates the market's unmet need, providing a powerful, firsthand perspective that strengthens the company's mission and investor pitch.

Episode 216 - Tom Ciulla - CEO Ikarovec thumbnail

Episode 216 - Tom Ciulla - CEO Ikarovec

The BioHub - by Avetix·3 months ago

Ikarovec De-risked its Preclinical Gene Therapy for Investors Across Four Key Areas

To attract investors in a tough market, Ikarovec CEO Tom Ciulla demonstrated progress beyond basic science. He highlighted strong preclinical data in multiple models, a completed non-human primate dose study, positive FDA feedback on their strategy, and a developed scalable manufacturing process.

Episode 216 - Tom Ciulla - CEO Ikarovec thumbnail

Episode 216 - Tom Ciulla - CEO Ikarovec

The BioHub - by Avetix·3 months ago

Ikarovec's Gene-Agnostic Therapy Strategy Targets Larger Patient Populations Missed by Precision Medicine

Unlike therapies targeting specific gene mutations, Ikarovec is developing a "gene-agnostic" treatment for retinitis pigmentosa. This approach significantly broadens the addressable market by offering a potential solution for a wide swath of patients whose mutations aren't amenable to current or developing therapies.

Episode 216 - Tom Ciulla - CEO Ikarovec thumbnail

Episode 216 - Tom Ciulla - CEO Ikarovec

The BioHub - by Avetix·3 months ago

Biotech Ikarovec Thrives Outside the UK's 'Golden Triangle' by Leveraging a Niche Hub

Ikarovec is headquartered in Norwich, not a major UK biotech hub. CEO Tom Ciulla frames this as a strength, citing Norwich Research Park's incubator facilities, cost-effective operations, and access to a talent pipeline of postdocs and PhDs from the local University of East Anglia.

Episode 216 - Tom Ciulla - CEO Ikarovec thumbnail

Episode 216 - Tom Ciulla - CEO Ikarovec

The BioHub - by Avetix·3 months ago

For Preclinical Biotechs, Investor Confidence Hinges on the Leadership Team's Proven Track Record

In a tough funding market for companies without clinical data, Ikarovec's CEO notes that investors heavily weigh the team's credibility. The combination of his own experience with FDA approvals, a seasoned CSO, and a board with multiple billion-dollar exits is a key factor that resonates with investors.

Episode 216 - Tom Ciulla - CEO Ikarovec thumbnail

Episode 216 - Tom Ciulla - CEO Ikarovec

The BioHub - by Avetix·3 months ago